Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer

• Status: Unknown status
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Apatinib has been proved to be effective and safe among patients in advanced colorectal cancer in several trials. the investigators aimed to evaluate its efficacy and safety as the neoadjuvant therapy in real world practice, and to explore factors associated with efficacy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sichuan Provincial People's Hospital
• Collaborator: Jiangsu HengRui Medicine Co., Ltd.
• Treatments: Apatinib; Fluorouracil; Leucovorin; Oxaliplatin

Criteria

Inclusion Criteria:

• Age of 18 years or older.

• Histological or cytological confirmation of adenocarcinoma of the colon or/and rectum;

• Stage TxNxM1 (truly metastatic disease) with liver metastases only.

• Patients should be voluntary to the trial and provide with signed informed consent.

• The researchers believe patients can benefit from the study.

Exclusion Criteria:

• Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories.

• Pregnant or lactating women

• Patients with Apatinib contraindications

• Patients of doctors considered unsuitable for the trial